METHODS FOR ASSESSMENT AND TREATMENT OF MOOD DISORDERS VIA SINGLE NUCLEOTIDE POLYMORPHISMS ANALYSIS

• US 20110237537A1
• Filed: 03/29/2011
• Published: 09/29/2011
• Est. Priority Date: 05/29/2009
• Status: Abandoned Application

• Current Assignee: Genomind, LLC
• Original Assignee: Genomind, LLC
• Inventors: Lombard, Jay L.
• Application Number:
  US13/074,967
• Publication Number:
  US 20110237537A1
• Time in Patent Office: Days
• US Class Current: 514/46
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 31/41 having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are included based on the relationships of the proteins encoded by the genes in the context of particular signaling pathways and provide a diagnostically relevant nexus. Also described herein are methods of presenting the data collected by the screen, including methods of delivering interpretive comments and/or treatment guidance based on the results of the genetic screening either individually or based on the genetic composition of particular clusters of genes which may be related to each other. Importantly, drugs which modulate these genetic disturbances are described for targeted therapeutic use based upon companion diagnostic method.

Claims

1. A panel assay to determine the presence of SNPs that alter the time on or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the drug metabolism pathway.

2. The panel assay of claim 1, further comprising a report with one or more interpretive comments indicating the effect of any identified SNPs on the regulation of these pathways.

3. The panel assay of claim 1, further comprising an interpretive comment suggesting a treatment based on identified SNPs.

4. The panel assay of claim 1, wherein the SNP indicator indicates an SNP that alters the function or expression of the SERT gene in the serotonin metabolism pathway.

5. The panel assay of claim 1, wherein the SNP indicator indicates an SNP that alters the function or expression of the DRD2 genes in the dopamine metabolism pathway.

6. The panel assay of claim 1, wherein the SNP indicator indicates an SNP that alters the function or expression of the CACNA1C gene in the glutamate metabolism pathway.

7. The panel assay of claim 1, wherein the SNP indicator indicates an SNP that alters the function or expression of genes that regulate methylatoin and/or drug metabolism, including:

MTHFR, COMT and/or CYP2D6.

8. The panel assay of claim 1, wherein the SNP indicators BDNF pathway comprise PCR-based assays.

9. The assay of claim 1, further comprising an interpretive comment suggesting a treatment based on identified SNPs.

10. The assay of claim 9, wherein the SNP indicator indicates an SNP that alters the function or expression of the SERT related genes in the serotonin metabolism pathway.

11. The assay of claim 9, wherein the SNP indicator indicates an SNP that alters the function or expression of the MTHF, or COMT genes in the methylation pathway.

12. The assay of claim 9, wherein the SNP indicator indicates an SNP that alters the function or expression of the CACNA1C genes in the glutamate metabolism pathway.

13. The assay of claim 9, wherein the SNP indicator indicates an SNP that alters the function or expression of the FKBP5 genes or BDNF in the hypothalamic pituitary adrenal axis.

14. A mood disorder panel assay to guide therapeutic treatment by determining the presence of SNPs that alter the function or expression of:

the SERT gene;

one or more of;

DRD2, MTHF, COMT genes;

one or more of;

CACNA1C; and

one or more of MTHFR, COMT and/or CYP2D6.

15. A mood disorder panel assay to determine the presence of SNPs that contribute to a mood disorder, the panel assay comprising:

a plurality of SNP indicators that collectively indicate the presence or absence of one or more SNP that alters the function or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the hypothalamic pituitary adrenal axis; and

an interpretive comment suggesting a treatment based on the identified SNPs.

16. A method of treating a patient for a mood disorder comprising:

determining the genotype of a polymorphism in each of the SERT, BDNF, CACNA1C, MTHFR/COMT and DRD2 genes;

advising a treatment based upon the results of said testing.

17. A method of treating a patient for a mood disorder comprising:

determining the genotype of a polymorphism in each of the SERT, BDNF, CACNA1C, MTHFR/COMT and DRD2 genes;

advising a treatment based upon the results of said testing wherein the treatment comprises;

prescribing at least one of tianeptine and other SSRE for patients having a SERT short allele;

prescribing at least one of Aniracetam and Nefiracetam for patients having the Val66Met form of BDNF;

prescribing at least one of a calcium channel antagonists, an L-type voltage gated calcium channel agonist, and a member of the ARB class of drugs, and Candesartan for patients having either the rs1006737 or the rs1006737 variant of CACNA1C;

prescribing at least one of a methylating agent, MTHF, S adenosylmethionine, a dopamine agonists, a MAO inhibitor, and a stimulant, for patients having either the C677T MTHFR variant or the 158val/val allele of the COMT gene; and

prescribing at least one of an atypical neuroleptics which preferentially inhibits 5HT2A over DRD2 and Clozaril for patients having the −

141C Ins/Del.

18. A method of treating a patient for a mood disorder comprising:

determining the genotype of a polymorphism in each of the SERT, BDNF, CACNA1C, MTHFR/COMT and DRD2 genes;

providing a treatment based upon the results of said testing, wherein the treatment comprises;

prescribing at least one of tianeptine and other SSRE for patients having a SERT short allele;

prescribing at least one of Aniracetam and Nefiracetam for patients having the Val66Met form of BDNF;

prescribing at least one of a calcium channel antagonists, an L-type voltage gated calcium channel agonist, and a member of the ARB class of drugs, and Candesartan for patients having either the rs1006737 or the rs1006737 variant of CACNA1C;

prescribing at least one of a methylating agent, MTHF, S adenosylmethionine, a dopamine agonists, a MAO inhibitor, and a stimulant, for patients having either the C677T MTHFR variant or the 158val/val allele of the COMT gene; and

prescribing at least one of an atypical neuroleptics which preferentially inhibits 5HT2A over DRD2 and Clozaril for patients having the −

141C Ins/Del.